World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
129
Citations
73976
World Ranking
2556
National Ranking
265

Christopher P. Denton publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christopher P. Denton sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,058 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christopher P. Denton D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher P. Denton sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 129 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christopher P. Denton is affiliated with University College London in the United Kingdom. Their research primarily focuses on topics related to systemic sclerosis and related diseases, interstitial lung diseases and idiopathic pulmonary fibrosis, dermatologic treatments and research, inflammatory myopathies and dermatomyositis, mast cells and histamine, pulmonary hypertension research and treatments, and skin diseases and diabetes.

The primary fields of study where Denton has contributed include Medicine, with significant subfields in pathology and forensic medicine, pulmonary and respiratory medicine, dermatology, epidemiology, and immunology.

Denton frequently publishes in several venues, including the following:

  • Lara D. Veeken
  • Annals of the Rheumatic Diseases
  • Arthritis & Rheumatology
  • Journal of Scleroderma and Related Disorders
  • The Lancet Rheumatology

Their research collaboration network includes frequent co-authors such as:

  • Voon H Ong
  • Yannick Allanore
  • Dinesh Khanna
  • Marco Matucci-Cerinic
  • Oliver Distler

Several recent publications highlight Denton's work, including:

  • "Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial," 2020, The Lancet Respiratory Medicine
  • "Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis," 2020, Autoimmunity Reviews
  • "Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial," 2022, The Lancet Respiratory Medicine
  • "Predictors of progression in systemic sclerosis patients with interstitial lung disease," 2020, European Respiratory Journal
  • "Definition, classification and diagnosis of pulmonary hypertension," 2024, European Respiratory Journal

Best Publications

  • 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative

    Frank Van Den Hoogen;Dinesh Khanna;Jaap Fransen;Sindhu R. Johnson

  • Updated clinical classification of pulmonary hypertension

    Gerald Simonneau;Michael A Gatzoulis;Ian Adatia;David Celermajer

  • Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

    Gérald Simonneau;Gérald Simonneau;David Montani;David Montani;David S. Celermajer;Christopher P. Denton

  • Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

    Anthony J. Tyndall;Bettina Bannert;Madelon Vonk;Paolo Airò

  • Interstitial lung disease in systemic sclerosis: a simple staging system.

    Nicole S. L. Goh;Sujal R. Desai;Srihari Veeraraghavan;David M. Hansell

  • Update of EULAR recommendations for the treatment of systemic sclerosis

    Otylia Kowal-Bielecka;Jaap Fransen;Jerome Avouac;Mike Becker;Mike Becker

  • Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

    U A Walker;A Tyndall;L Czirják;C Denton

  • Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

    D Mukerjee;D St George;B Coleiro;C Knight

  • A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

    Rachel K Hoyles;Ross W Ellis;Jessica Wellsbury;Belinda Lees

  • Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

    J. H. Korn;Maureen D Mayes;M. Matucci Cerinic;M. Rainisio

  • A myocardial lineage derives from Tbx18 epicardial cells

    Chen-Leng Cai;Jody C. Martin;Yunfu Sun;Li Cui

  • Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

    J Gerry Coghlan;Christopher P Denton;Ekkehard Grünig;Diana Bonderman

  • EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

    O. Kowal-Bielecka;R. Landewé;J. Avouac;S. Chwiesko

  • Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

    Dinesh Khanna;Christopher P Denton;Angelika Jahreis;Jacob M van Laar

  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

    Dinesh Khanna;Celia J F Lin;Daniel E Furst;Jonathan Goldin

  • Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

    Marco Matucci-Cerinic;Christopher P Denton;Daniel E Furst;Maureen D Mayes

  • Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

    Christopher P. Denton;Peter A. Merkel;Daniel E. Furst;Dinesh Khanna

  • Scleroderma renal crisis: patient characteristics and long-term outcomes.

    H. Penn;A.J. Howie;E.J. Kingdon;C.C. Bunn

  • Prediction of pulmonary complications and long-term survival in systemic sclerosis.

    Svetlana I. Nihtyanova;Benjamin E. Schreiber;Voon H. Ong;Daniel Rosenberg

  • Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.

    Xu Shi-Wen;Yunliang Chen;Christopher P. Denton;Mark Eastwood

Frequent Co-Authors

David Abraham
David Abraham University College London
Carol M. Black
Carol M. Black University College London
Marco Matucci-Cerinic
Marco Matucci-Cerinic University of Florence
Oliver Distler
Oliver Distler University of Zurich
Dinesh Khanna
Dinesh Khanna University of Michigan–Ann Arbor
Yannick Allanore
Yannick Allanore Université Paris Cité
Ariane L. Herrick
Ariane L. Herrick University of Manchester
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Janet E. Pope
Janet E. Pope University of Western Ontario
Ulf Müller-Ladner
Ulf Müller-Ladner University of Giessen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in advancing your medical career or exploring alternative pathways, a variety of related online degrees are available to broaden your options beyond traditional medicine. For those interested in healthcare management, a health administration degree online provides the skills needed to lead medical staff and manage organizational operations efficiently.

Many aspiring leaders consider the most affordable online mha programs to gain advanced training in healthcare policy, law, and financial management. Practicing nurses can explore career growth and specialization with the best dnp programs online, which prepare them for executive or high-impact clinical roles.

Additionally, those passionate about pharmaceuticals can pursue a pharmacy degree online to become a licensed pharmacist, contributing to patient care through medication expertise and research. These diverse online programs help students balance their studies with other responsibilities, making advanced healthcare roles more accessible than ever.

Best Scientists Citing Christopher P. Denton

Trending Scientists

Recently Published Articles